Chronic Fibrosing Interstitial Lung Disease
1 medicine
Chronic fibrosing interstitial lung disease (ILD) is a group of progressive conditions that scar lung tissue, causing worsening breathlessness over time. Antifibrotic medicines such as nintedanib slow the rate of scarring.
Key facts
- Chronic fibrosing interstitial lung disease (ILD) is a group of conditions in which lung tissue gradually scars and stiffens, reducing the lungs' ability to move oxygen into the blood.
- The scarring is generally irreversible, so early recognition matters more than with many lung conditions.
- Common subtypes include idiopathic pulmonary fibrosis (IPF) and fibrosis linked to autoimmune conditions such as rheumatoid arthritis or systemic sclerosis.
- Antifibrotic medicines such as nintedanib slow the rate of scarring; they do not reverse damage already done.
What chronic fibrosing ILD is
Chronic fibrosing interstitial lung disease refers to a group of conditions in which lung tissue gradually scars and stiffens. The scarring, known as fibrosis, reduces the lungs' ability to transfer oxygen into the bloodstream. Over time, the damage accumulates and is generally irreversible, which makes early recognition important.
How it develops
Most forms of fibrosing ILD share a common pattern: the immune system or an environmental trigger sets off repeated cycles of inflammation and repair that leave fibrous scar tissue behind. Common subtypes include idiopathic pulmonary fibrosis (IPF) and fibrosis occurring alongside autoimmune conditions such as rheumatoid arthritis or systemic sclerosis. Persistent dry cough and exertional breathlessness that steadily worsens are the hallmark symptoms. A respiratory specialist typically confirms the diagnosis using high-resolution CT imaging and lung function testing.
How it is treated
Antifibrotic therapy slows the rate of fibrosis rather than reversing existing damage. Nintedanib is one of the established antifibrotic agents used in this setting, part of the broader field of respiratory medicines targeting disease progression. Pulmonary rehabilitation, breathing exercises, and supplemental oxygen support quality of life alongside drug treatment.
When to see a doctor
Anyone experiencing progressive breathlessness or a new persistent cough that does not resolve should seek specialist respiratory assessment promptly. Earlier diagnosis gives antifibrotic treatment more lung function to protect.
This page is educational and does not replace advice from a doctor or pharmacist who knows your health history.